Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Pericardial Effusion Revealing Fluid Overload-Associated Large B-Cell Lymphoma After Left Atrial Appendage Closure.

Created on 04 Nov 2026

Authors

Ying Gu, Jianhua Li

Published in

JACC. Case reports. Pages 110980. Nov 04, 2026. Epub Nov 04, 2026.

Abstract

Fluid overload-associated large B-cell lymphoma (FO-LBCL) is a rare malignancy presenting with serous effusions without solid masses.
We report an 83-year-old man developing substantial pericardial effusion 19 months post-left atrial appendage closure. Although a device-related complication was initially suspected, pericardial fluid analysis and fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography established a definitive diagnosis of FO-LBCL. Because of severe cardiovascular comorbidities and anthracycline cardiotoxicity risks, standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone was contraindicated. Instead, an individualized, anthracycline-free regimen with 3 cycles of rituximab monotherapy followed by 3 cycles of rituximab, cyclophosphamide, vincristine, and prednisolone cycles was administered. The patient achieved remission and remained recurrence-free during 18-month follow-up.
The present case highlights the critical need to exclude malignancies in post-left atrial appendage closure effusions and demonstrates the efficacy of attenuated, anthracycline-free chemoimmunotherapy for elderly patients with FO-LBCL high cardiovascular risk.

PMID:
42980624
Bibliographic data and abstract were imported from PubMed on 04 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 12
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement